Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07355491 · ClinicalTrials.gov registry record
Performance Evaluation of Dream OCT: AP Study
A clinical trial of Glaucoma Patients and Retina Patients, sponsored by Intalight.
- Recruiting
- Registry status
- 120
- Enrollment target
- 1
- Study location
NCT07355491: Recruiting study of Glaucoma Patients and Retina Patients, sponsored by Intalight.
NCT07355491 is a study of Glaucoma Patients and Retina Patients that is actively recruiting participants, run by Intalight. The registered enrollment target is 120 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07355491, a study of Glaucoma Patients and Retina Patients, is actively recruiting participants, sponsored by Intalight.
- RECRUITING
- Registry status
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the clinical performance of a new swept-source OCT imaging device, the VG200D, and to evaluate substantial equivalence with a predicate device, the Cirrus 5000. Clinical performance will be assessed through an agreement and precision analysis of OCT measurement parameters.
Primary Outcome
Primary endpoints include the agreement and precision results from the Anterior Segment OCT measurements for cornea and epithelial thickness in normal eyes and eyes with a corneal abnormality and the posterior segment OCT measurements for the retina, ganglion cell +IPL, RNFL, and optic nerve in normal eyes, eyes with glaucoma, and eyes with retinal pathology.
Conditions Studied
Interventions
- DEVICE This is an observational study only, all patients are imaged on the investigational device
Study Locations (1)
Illinois
- Illinois College of Optometry - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-12-16 |
| Est. Completion | 2026-04 |
What NCT07355491 shows while recruiting
NCT07355491 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap.
The record links to 4 conditions, with Glaucoma Patients appearing as the primary indexed condition, and to 1 intervention - of which This is an observational study only, all patients are imaged on the investigational device is the first listed.
NCT07355491 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT07355491 about?
NCT07355491 is a clinical study titled "Performance Evaluation of Dream OCT: AP Study". This study will evaluate the clinical performance of a new swept-source OCT imaging device, the VG200D, and to evaluate substantial equivalence with a predicate device, the Cirrus 5000. Clinical performance will be assessed through an agreement and precision analysis of OCT measurement parameters.
What is the current status of trial NCT07355491?
This trial is currently recruiting. The enrollment target is 120 participants. The study started on 2025-12-16. Estimated completion is 2026-04.
What conditions does trial NCT07355491 study?
This clinical trial studies the following conditions: Glaucoma Patients, Retina Patients, Eyes With Corneal Abnormality, Normal Healthy Eyes.
What interventions are being tested in trial NCT07355491?
The interventions under investigation include: This is an observational study only, all patients are imaged on the investigational device (DEVICE).
Who is sponsoring clinical trial NCT07355491?
This trial is sponsored by Intalight, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07355491 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI